Skip to content
Unichem Laboratories logo

Unichem Laboratories

UNICHEMLAB NSE
₹488.80 7.70 (1.60%)
Market Cap
₹3,441 Cr
P/E
11.29

Unichem Laboratories (UNICHEMLAB) share price was ₹488.80 at the 28 Oct 2026 close; market capitalisation ₹3,441 Cr; P/E (TTM) 11.29; sector Healthcare. The share price rose 5.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 20.1% year on year to ₹632.6 Cr and net profit was ₹41 Cr, against −₹10 Cr a year earlier (compared with Jun 2025). Promoters held 70.22% of Unichem Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹488.80 +23.25 +4.99% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹3,441 Cr
P/E (TTM)
11.29
EBITDA
₹247 Cr
Return on Equity
9.3%
Debt to Equity
0.18
Book Value
₹385.97
EPS (TTM)
₹43.29
52W High
₹687.20
52W Low
₹278.20

Price-based figures as of 28 Oct 2026, 15:53 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Unichem Laboratories (this company)
₹488.8011.293,441 Cr1.270.83%9.30%11.36%2,655 Cr304 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.72%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
56 Good
Overall score
Data confidence 100/100

Category scores

Quality Weak 37
Returns, margins, earnings quality 22%
Valuation Strong 90
Cheap vs sector & own history 24%
Growth Poor 27
Sales & profit trajectory 9%
Financial Health Good 58
Solvency, leverage, coverage 9%
Momentum Good 56
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 25.0% CAGR over last 5 years

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 2.34% over last 3 years.
  • Earnings include an other income of Rs.277 Cr.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

BearishNeutralBullish

Bearish

Bearish
10
Neutral
6
Bullish
3

Moving Averages

BearishNeutralBullish

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
5.53% lower than 3Y

change over 1 year

Net Income Growth
83.85% higher than 3Y

change over 1 year

Cash Flow Change
152%

change over 1 year

EBITDA Margin Change
-21.94%

change over 1 year Operating margin 11% · Jun 2026

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Unichem Laboratories trades at a market cap of Rs.3,339 Cr with a PE of 13.2x and PB of 1.23x. While the company delivered 25% profit CAGR over 5 years, recent performance shows a sharp TTM profit decline of 40% and a low 3-year average ROE of approximately 2%, raising questions about earnings quality and sustainability.

Bull Case 7
  • Strong 5-year compounded profit growth of 25% CAGR indicates long-term earnings recovery trajectory
  • Reasonable valuation at PE of 13.2x, below many healthcare sector peers in India
  • Price-to-book ratio of 1.23x suggests limited downside from asset value perspective
  • Compounded sales growth of 18% over 3 years demonstrates revenue momentum
  • 5-year compounded sales growth of 12% shows consistent top-line expansion above industry average
  • 3-year compounded profit growth of 35% CAGR reflects operational improvement in recent years
  • Stock CAGR of 8% over 5 years and 6% over 10 years shows steady long-term wealth creation
Bear Case 8
  • TTM profit declined sharply by 40%, signaling potential earnings deterioration
  • 3-year average ROE of just 2% indicates very poor capital efficiency and weak return generation
  • Earnings include other income of Rs.260 Cr, raising concerns about core operating profit quality
  • 5-year average ROE of 0% suggests the company barely generated returns on equity over a half-decade
  • Company is not paying meaningful dividends despite reporting profits, with yield at only 0.85%
  • Stock has declined 21% over the past 1 year, reflecting negative market sentiment
  • 10-year compounded profit growth is negative at -3% CAGR, showing long-term earnings weakness
  • TTM sales growth has slowed to just 4%, a significant deceleration from the 18% 3-year CAGR

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

114d ago
Positives 2
  • Net profit surges 84% YoY Jul 3

    Consolidated net profit rose to ₹252.84 crores in FY26 from ₹137.52 crores in FY25, an 84% jump. Consolidated revenue grew 4.31% to ₹2,201.85 crores.

  • Strong ESG and emission cuts Jul 3

    Unichem reduced Scope 1 and 2 emissions by 26% and recycled 84% of treated effluent in FY26, strengthening its sustainability profile.

Neutral 3
  • Exports dominate at 97.6% revenue Jul 3

    Exports accounted for 97.6% of total turnover in FY26, indicating heavy reliance on international markets.

  • Trading window shut for Q1 results Jun 23

    Trading window closed from July 1, 2026 until 48 hours after Q1FY27 results are disclosed publicly.

  • 63rd AGM set for Aug 11 Jun 10

    AGM scheduled for August 11, 2026 via video conference with shareholder cut-off date of August 4, 2026.

TL;DR: Unichem Laboratories delivered a strong FY26 with an 84% surge in net profit on modest 4.3% revenue growth, suggesting significant margin expansion. The company is almost entirely export-driven at 97.6% of revenue, which limits domestic diversification but benefits from global pharma demand. No material headwinds surfaced in recent filings. The trend is improving, with profitability gains and ESG progress, though investors should watch for currency and geopolitical risks given the heavy export dependence.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
423
416
466
432
483
507
533
587
527
579
521
575
633
Expenses
395
407
435
406
443
452
448
503
504
513
476
527
563
Operating Profit
28
9
31
25
40
55
86
84
22
66
45
48
70
OPM %
7%
2.1%
7%
6%
8%
11%
16%
14%
4.3%
11%
9%
8%
11%
Other Income
9
6
79
-119
4
9
14
9
7
-37
287
11
16
Interest
6
7
6
5
4
5
7
5
7
8
7
9
7
Depreciation
29
29
32
27
32
32
31
30
32
31
31
31
30
PBT
2
-22
73
-126
8
27
62
58
-9
-11
293
19
49
Tax %
132%
12%
0%
3%
74%
9%
6%
8%
16%
10%
10%
42%
15%
Net Profit
-1
-24
73
-129
2
25
58
53
-10
-12
264
11
41
EPS (₹)
-0.1
-3.48
10.4
-18.37
0.29
3.5
8.22
7.52
-1.49
-1.69
37.54
1.55
5.89
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,202
1,333
698
815
1,180
1,104
1,235
1,270
1,343
1,785
2,111
2,202
2,308
Expenses
1,100
1,169
738
942
1,254
1,153
1,144
1,198
1,389
1,698
1,846
2,013
2,079
Operating Profit
101
164
-41
-128
-74
-49
91
72
-46
87
265
189
229
OPM %
8%
12%
-6%
-16%
-6%
-4.5%
7%
6%
-3.4%
4.9%
13%
9%
10%
Other Income
20
15
184
2,735
91
91
50
47
0
-26
35
260
277
Interest
3
3
3
8
8
8
5
6
17
23
21
32
32
Depreciation
41
39
44
51
67
82
84
91
113
123
125
125
123
PBT
77
137
97
2,548
-58
-48
51
22
-176
-85
155
292
350
Tax %
3%
21%
-12%
0%
-59%
25%
33%
-50%
15%
10%
11%
14%
—
Net Profit
75
108
109
2,545
-24
-60
34
33
-202
-94
138
253
305
EPS (₹)
8.31
11.9
11.96
362
-3.38
-8.55
4.87
4.7
-28.72
-13.32
19.53
35.91
43.29
Div. Payout %
24%
17%
25%
1%
-118%
-47%
82%
85%
-14%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
18
18
18
14
14
14
14
14
14
14
14
14
Reserves
849
936
1,045
2,666
2,606
2,517
2,543
2,604
2,421
2,424
2,437
2,703
Borrowings
22
36
98
151
200
206
119
349
314
248
460
500
Other Liabilities
264
283
359
359
323
407
436
351
444
589
659
489
Total Liabilities
1,153
1,274
1,521
3,190
3,142
3,145
3,112
3,319
3,193
3,275
3,569
3,707
Fixed Assets
416
403
491
578
810
870
884
990
1,257
1,252
1,300
1,213
CWIP
123
237
250
238
92
330
568
494
147
123
31
100
Investments
41
14
14
901
926
550
392
264
2
1
0
0
Other Assets
574
620
766
1,473
1,313
1,395
1,269
1,571
1,787
1,898
2,239
2,394
Total Assets
1,153
1,274
1,521
3,190
3,142
3,145
3,112
3,319
3,193
3,275
3,569
3,707
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
78
112
68
-112
-328
20
33
-260
-85
14
-7
4
Investing
-52
-85
-132
1,648
-286
-36
-66
100
241
63
-242
194
Financing
-51
-33
59
-881
-2
-62
-121
191
-81
-106
184
2
Net Cash Flow
-25
-7
-4
655
-616
-78
-154
32
75
-29
-65
200
Free Cash Flow
4
-28
-79
-271
-519
-360
-254
-386
-123
0
-142
163
CFO/OP
95
87
-237
89
424
-49
52
-350
160
23
4
6
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
58
60
165
124
135
129
74
142
160
131
135
137
Inventory Days
171
184
397
278
278
374
518
527
414
365
418
349
Days Payable
114
131
297
230
182
236
202
161
193
174
164
128
Cash Conversion Cycle
116
113
265
172
231
267
390
508
382
322
389
358
Working Capital Days
88
90
174
133
165
154
163
207
207
173
159
169
ROCE %
9%
15%
9%
128%
-2%
-2%
2%
1%
-5%
0%
6%
4%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Unichem Laboratories insights

69 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

FIIs2.70%Promot.70.22%Others2.78%DIIs9.40%Public14.90%As ofSep 2026

Documents

Frequently Asked Questions about Unichem Laboratories

What does Unichem Laboratories Ltd do?
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas.[1]
Where is Unichem Laboratories Ltd (UNICHEMLAB) listed?
Unichem Laboratories Ltd trades as UNICHEMLAB on the NSE and under code 506690 on the BSE.
Which sector does Unichem Laboratories Ltd belong to?
Unichem Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Unichem Laboratories Ltd?
Unichem Laboratories Ltd has a market capitalisation of ₹3,441 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Unichem Laboratories Ltd?
Unichem Laboratories Ltd trades at a PE ratio of 11.29 as of 28 Oct 2026, on earnings per share of ₹43.29, against a book value of ₹385.97 per share.
What is the 52-week high and low of Unichem Laboratories Ltd?
Over the last 52 weeks Unichem Laboratories Ltd has traded between ₹278.2 and ₹687.2 as of 28 Oct 2026.
Does Unichem Laboratories Ltd pay dividends?
Unichem Laboratories Ltd has a dividend yield of 0.83%.
What is the Return on Equity (ROE) of Unichem Laboratories Ltd?
Unichem Laboratories Ltd reported a return on equity of 9.30%. Its debt-to-equity ratio is 0.18.

Company Information

Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Website unichemlabs.com
CEO Mr. Pabitra Kumar Kalipada Bhattacharyya
Employees 3,142
Listed 2001-02-07
Face Value ₹ 2
Shares Outstanding 7,04,05,750

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/UNICHEMLAB.md for Unichem Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month